



# Kilitch Drugs (India) Ltd.

**November 24, 2020**

To,  
Corporate Listing Department  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE - KILITCH**

**Ref: Your letter no.NSE/LIST/ 17565 dated 20<sup>th</sup> November, 2020.**

Dear Sir,

**Sub: Corrigendum to Annual Report of the Company for the Financial Year 2019-20**

The Members/Shareholders of the Company are requested to note the corrections as appearing hereunder with respect to and in connection with the Annual Report of the Company for the Financial Year 2019-20 as dispatched to its Members/Shareholders of the Company. A Corrigendum has also been displayed on the website of the Company [www.kilitch.com](http://www.kilitch.com).

- We wish to inform to our shareholders /Members for the below mentioned modification with respect to the Corporate Governance Report addition of Note. 13 on page number 52.

Details of total fees for all services paid by the Company and its subsidiaries, on a standalone and consolidated basis, to the statutory auditor of all entities in the network firm/ network entity of which the statutory auditor is a part, as mentioned in Note 37 as auditors remuneration of Notes to Accounts of both the standalone as well as consolidated Financials as published through annual reports for the Financial Year 2019-20, are as below

## Standalone

Particulars	2019-20 (Rs. In Lakhs)	2018-19 (Rs. In Lakhs)
Audit Fees	15.00	15.00
Other Professional Fees		7.50
Total	15.00	22.50

## Consolidated

Particulars	2019-20 (Rs. In Lakhs)	2018-19 (Rs. In Lakhs)
Audit Fees	15.30	15.60
Other Professional Fees		7.50
Total	15.30	23.10





Kilitch Drugs (India) Ltd.

We further wish to inform you that the said disclosure has no impact on the standalone & Consolidated Statement of Profit and Loss of the Company for the financial year ended 31st March, 2020, as the disclosure mentioned in the corrigendum, were considered properly for the preparation of Standalone & Consolidated Statement of Profit and Loss as specified in Note 37 as auditors remuneration and that this corrigendum should be read in conjunction with the printed Annual Report 2019-2020. Except for the specific changes as mentioned in the Corrigendum, there is no other revision in the printed Annual Report 2019-2020.

In this connection, we sincerely regret for the inconvenience caused. We request you to take the above corrections on your record.

Thanking you,

Yours faithfully,  
**For Kilitch Drugs (India) Limited**

  
**Sunita Gohil**  
**Company Secretary**  
Encl:a/a

